Ask about this productRelated genes to: SPG20 antibody
- Gene:
- SPART NIH gene
- Name:
- spartin
- Previous symbol:
- SPG20
- Synonyms:
- KIAA0610, TAHCCP1
- Chromosome:
- 13q13.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-01-20
- Date modifiied:
- 2017-05-30
- Gene:
- SPART-AS1 NIH gene
- Name:
- SPART antisense RNA 1
- Previous symbol:
- C13orf43, SPG20OS, SPG20-AS1
- Synonyms:
- -
- Chromosome:
- 13q13.3
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2011-04-12
- Date modifiied:
- 2017-06-29
Related products to: SPG20 antibody
Related articles to: SPG20 antibody
- Neutrophil extracellular traps (NETs) could entrap tumour cells and promote their dissemination and metastasis. Further analysis of NETs-related molecules is expected to provide a new strategy for prognosis prediction and treatment of lung adenocarcinoma (LUAD) patients. - Source: PubMed
Publication date: 2023/11/19
Wang HuanShi YueliXu XiaXu ShuminShi YutingChen WeiyuWang Kai - Clear cell renal cell carcinoma (ccRCC) is a primary malignant tumour of tubular epithelial origin and is most common in the urinary tract. Growing evidence suggests that oxidative stress (OS), generates high levels of reactive oxygen species (ROS) and free radicals, and plays a critical role in cancer in humans. However, the predictive value of OS-related long non-coding RNAs (lncRNAs) in ccRCC remains unclear. We constructed a predictive signature of survival based on OS-related lncRNAs that were obtained from The Cancer Genome Atlas (TCGA-KIRC), to predict the prognosis of patients with ccRCC. The signature comprised seven lncRNAs: SPART-AS1, AL162586.1, LINC00944, LINC01550, HOXB-AS4, LINC02027, and DOCK9-DT. OS-related signature of lncRNAs had diagnostic efficiency higher than that of clinicopathological variables, with an area of 0.794 under the receiver operating characteristic curve. Additionally, the nomogram based on risk scores and clinicopathological variables (age, gender, grade, stage, M-stage, and N-stage) showed strong predictive performance. Patients with high-risk were found to be more sensitive to the therapeutic drugs ABT.888, AICAR, MS.275, sunitinib, AZD.2281, and GDC.0449. Our constructed the predictive signature can independently predict the prognosis of patients with ccRCC; however, the underlying mechanism needs further investigation. - Source: PubMed
Publication date: 2023/04/07
Zhang YuZhou GuozhongShi WeiShi WeiliHu MeijunKong DefuLong RongChen Nan